Integrum moves into Turkey

Mölndal, Sweden – October 27, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.

As part of Integrum’s efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today started a collaboration in Turkey with Medikon (www.medikon.net).

“The collaboration with Medikon secures a foothold in the Turkish market for Integrum’s unique solutions, a country where orthopedic healthcare is strongly marked by the earthquake that occurred earlier this year. There is a great need for innovative orthopedic solutions, and we are happy to be able to help improve the quality of life for amputees with our OPRA™ Implant System,” said Rickard Brånemark, CEO of Integrum.

ABOUT INTEGRUM

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.